Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Bought by Capital Research Global Investors

Capital Research Global Investors grew its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 0.2% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 13,162,513 shares of the company's stock after acquiring an additional 25,309 shares during the period. Capital Research Global Investors owned about 0.41% of Takeda Pharmaceutical worth $174,272,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of TAK. Dimensional Fund Advisors LP raised its holdings in Takeda Pharmaceutical by 60.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 181,929 shares of the company's stock valued at $2,409,000 after acquiring an additional 68,200 shares in the last quarter. First Trust Advisors LP raised its stake in shares of Takeda Pharmaceutical by 2.0% in the 4th quarter. First Trust Advisors LP now owns 3,240,932 shares of the company's stock valued at $42,910,000 after purchasing an additional 62,718 shares in the last quarter. Forum Financial Management LP grew its stake in Takeda Pharmaceutical by 133.7% in the fourth quarter. Forum Financial Management LP now owns 114,324 shares of the company's stock worth $1,514,000 after purchasing an additional 65,399 shares in the last quarter. Marshall Wace LLP bought a new stake in Takeda Pharmaceutical in the fourth quarter valued at about $1,010,000. Finally, Mariner LLC raised its stake in Takeda Pharmaceutical by 14.0% during the fourth quarter. Mariner LLC now owns 142,504 shares of the company's stock valued at $1,887,000 after buying an additional 17,525 shares in the last quarter. 9.17% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Morgan Stanley upgraded Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research report on Wednesday, April 2nd.

Takeda Pharmaceutical Stock Performance

Shares of NYSE TAK traded down $0.08 during midday trading on Friday, hitting $15.03. The company's stock had a trading volume of 2,188,239 shares, compared to its average volume of 1,865,662. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31. Takeda Pharmaceutical Company Limited has a 1-year low of $12.58 and a 1-year high of $15.37. The firm's fifty day moving average price is $14.72 and its 200-day moving average price is $13.94. The firm has a market cap of $47.82 billion, a P/E ratio of 37.58, a P/E/G ratio of 0.24 and a beta of 0.39.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last announced its quarterly earnings results on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, topping analysts' consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. On average, sell-side analysts forecast that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.